|
|
Article: Amalyte and Meiji Enter Into a License, Development and Commercialization Agreement on AM3301 and a Novel Class of Anti-Inflammatory Compounds.
- Article from:
- Clinical Trials Week
- Article date:
- June 22, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Amalyte Pharmaceuticals LLC (Amalyte), a member of the Kemin group of companies, has announced it has entered into a worldwide strategic alliance with Meiji Seika Kaisha Ltd. (Meiji) to discover, develop and commercialize a lead compound, ME3301 (now AM3301), and novel class of dual-acting anti-inflammatory compounds for a variety of human health applications (see also Amalyte Pharmaceuticals LLC).
Under the terms of the agreement, Amalyte will have exclusive rights to develop and commercialize collaboration products worldwide, except in Japan and several Asian countries where Meiji has a development and commercialization option for all products arising from the ...